OPKO Health, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OPKO Health, Inc. (OPK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.24 million for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-28
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.24M, a 1.22% increase year-over-year.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.73M, a 4.55% increase year-over-year.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.92M, a 4.83% decline year-over-year.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.97M, a 6.65% increase year-over-year.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.71M, a 3.02% decline from fiscal 2024.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.05M, a 3.20% decline from fiscal 2023.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.41M, a 38.34% decline from fiscal 2022.
- OPKO Health, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.51M, a 35.78% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.24M 10-Q/A · filed 2026-08-28 | $4.97M 10-Q/A · filed 2026-08-28 | $7.89M derived: sum of 3 quarters · filed 2026-08-28 | $10.86M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2026-03-31 | $2.73M 10-Q/A · filed 2026-08-28 | $5.65M derived: sum of 2 quarters · filed 2026-08-28 | $8.62M derived: sum of 3 quarters · filed 2026-08-28 | $10.83M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.89M derived: sum of 2 quarters · filed 2026-02-26 | $8.10M derived: sum of 3 quarters · filed 2026-08-28 | $10.71M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $2.97M 10-Q · filed 2025-10-29 | $5.18M derived: sum of 2 quarters · filed 2026-08-28 | $7.80M 10-Q · filed 2025-10-29 | $10.86M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-06-30 | $2.21M 10-Q/A · filed 2026-08-28 | $4.83M 10-Q/A · filed 2026-08-28 | $7.89M derived: sum of 3 quarters · filed 2026-08-28 | $10.68M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-03-31 | $2.62M 10-Q/A · filed 2026-08-28 | $5.68M derived: sum of 2 quarters · filed 2026-08-28 | $8.46M derived: sum of 3 quarters · filed 2026-08-28 | $11.07M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2024-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.85M derived: sum of 2 quarters · filed 2026-02-26 | $8.46M derived: sum of 3 quarters · filed 2026-02-26 | $11.05M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $2.78M 10-Q · filed 2025-10-29 | $5.39M derived: sum of 2 quarters · filed 2025-10-29 | $7.98M 10-Q · filed 2025-10-29 | $10.65M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $2.61M 10-Q · filed 2025-07-31 | $5.20M 10-Q · filed 2025-07-31 | $7.87M derived: sum of 3 quarters · filed 2026-02-26 | $11.09M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $2.59M 10-Q · filed 2025-05-01 | $0.00 10-Q · filed 2024-05-07 | $5.26M derived: sum of 2 quarters · filed 2026-02-26 | $8.48M derived: sum of 3 quarters · filed 2026-02-26 | $11.29M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.89M derived: sum of 2 quarters · filed 2026-02-26 | $8.70M derived: sum of 3 quarters · filed 2026-02-26 | $11.41M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $3.22M 10-Q · filed 2024-11-07 | $6.03M derived: sum of 2 quarters · filed 2024-11-07 | $8.74M 10-Q · filed 2024-11-07 | $11.94M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $2.81M 10-Q · filed 2024-08-07 | $5.53M 10-Q · filed 2024-08-07 | $8.72M derived: sum of 3 quarters · filed 2025-03-03 | $12.11M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $2.72M 10-Q · filed 2024-05-07 | $5.91M derived: sum of 2 quarters · filed 2025-03-03 | $9.30M derived: sum of 3 quarters · filed 2025-03-03 | $13.61M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $6.58M derived: sum of 2 quarters · filed 2025-03-03 | $10.89M derived: sum of 3 quarters · filed 2025-03-03 | $18.51M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $3.39M 10-Q · filed 2023-11-06 | $7.70M derived: sum of 2 quarters · filed 2023-11-06 | $15.31M 10-Q · filed 2022-11-08 | $19.02M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-06-30 | $4.31M 10-Q · filed 2023-08-03 | $15.31M 10-Q · filed 2023-11-06 | $11.93M 10-Q · filed 2022-08-04 | $15.63M derived: sum of 3 quarters · filed 2024-03-01 | $19.45M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2022-03-31 | $7.62M 10-Q · filed 2023-05-03 | $11.32M derived: sum of 2 quarters · filed 2024-03-01 | $15.14M derived: sum of 3 quarters · filed 2024-03-01 | $18.60M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2021-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $7.53M derived: sum of 2 quarters · filed 2024-03-01 | $10.98M derived: sum of 3 quarters · filed 2024-03-01 | $13.63M 10-K · filed 2024-03-01 | ||
| 2021-09-30 | $3.82M 10-Q · filed 2022-11-08 | $7.28M derived: sum of 2 quarters · filed 2022-11-08 | $9.93M 10-Q · filed 2022-11-08 | $12.10M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $3.46M 10-Q · filed 2022-08-04 | $6.11M 10-Q · filed 2022-08-04 | $8.28M derived: sum of 3 quarters · filed 2023-02-27 | $11.02M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $2.65M 10-Q · filed 2022-05-09 | $4.82M derived: sum of 2 quarters · filed 2023-02-27 | $7.56M derived: sum of 3 quarters · filed 2023-02-27 | $9.14M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2020-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $4.91M derived: sum of 2 quarters · filed 2023-02-27 | $6.50M derived: sum of 3 quarters · filed 2023-02-27 | $8.95M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $2.74M 10-Q · filed 2021-10-28 | $4.33M derived: sum of 2 quarters · filed 2021-10-28 | $6.78M 10-Q · filed 2021-10-28 | $9.19M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $1.59M 10-Q · filed 2021-07-29 | $4.04M 10-Q · filed 2021-07-29 | $6.45M derived: sum of 3 quarters · filed 2022-03-01 | $9.88M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $2.45M 10-Q · filed 2021-04-28 | $4.87M derived: sum of 2 quarters · filed 2022-03-01 | $8.29M derived: sum of 3 quarters · filed 2022-03-01 | $11.41M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.84M derived: sum of 2 quarters · filed 2022-03-01 | $8.96M derived: sum of 3 quarters · filed 2022-03-01 | $13.42M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $3.43M 10-Q · filed 2020-10-29 | $6.55M derived: sum of 2 quarters · filed 2020-10-29 | $11.01M 10-Q · filed 2020-10-29 | $16.18M derived: sum of 4 quarters · filed 2021-02-18 | ||
| 2019-06-30 | $3.12M 10-Q · filed 2020-07-31 | $7.58M 10-Q · filed 2020-07-31 | $12.75M derived: sum of 3 quarters · filed 2021-02-18 | $17.83M derived: sum of 4 quarters · filed 2021-02-18 | ||
| 2019-03-31 | $4.46M 10-Q · filed 2020-05-06 | $9.63M derived: sum of 2 quarters · filed 2021-02-18 | $14.70M derived: sum of 3 quarters · filed 2021-02-18 | $20.28M derived: sum of 4 quarters · filed 2021-02-18 | ||
| 2018-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $10.25M derived: sum of 2 quarters · filed 2021-02-18 | $15.82M derived: sum of 3 quarters · filed 2021-02-18 | $21.76M 10-K · filed 2021-02-18 | ||
| 2018-09-30 | $5.08M 10-Q · filed 2019-11-05 | $10.65M derived: sum of 2 quarters · filed 2019-11-05 | $16.59M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $5.58M 10-Q · filed 2019-08-07 | $11.51M 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | $5.94M 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $28.31M 10-K · filed 2020-03-02 | |||||
| 2016-12-31 | $42.69M 10-K · filed 2019-03-01 | |||||
| 2015-12-31 | $26.07M 8-K · filed 2019-01-29 | |||||
| 2014-12-31 | $14.74M 10-K · filed 2017-03-01 | |||||
| 2013-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $3.98M derived: sum of 2 quarters · filed 2016-02-29 | $5.78M derived: sum of 3 quarters · filed 2016-02-29 | $10.98M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $2.21M derived: sum of 2 quarters · filed 2013-11-12 | $7.41M 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $7.00M 10-Q · filed 2013-08-09 | ||||
| 2013-03-31 | $5.21M 10-Q · filed 2013-05-10 | |||||
| 2012-12-31 | $5.13M 10-K · filed 2015-02-27 | |||||
| 2011-12-31 | $7.16M 10-K · filed 2014-03-03 | |||||
| 2010-12-31 | $6.92M 10-K · filed 2013-03-18 | |||||
| 2009-12-31 | $4.50M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |